{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:19:38Z","timestamp":1790799578698,"version":"4.1.0"},"reference-count":228,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013101","name":"National Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.02130","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:37:40Z","timestamp":1599093460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":162,"title":["Viral Emerging Diseases: Challenges in Developing Vaccination Strategies"],"prefix":"10.3389","volume":"11","author":[{"given":"Maria","family":"Trovato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Sartorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"D\u2019Apice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Manco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiuseppe","family":"De Berardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5245021","article-title":"Emerging and neglected infectious diseases: insights, advances, and challenges.","volume":"2017","author":"Nii-Trebi","year":"2017","journal-title":"Biomed Res Int."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00549","article-title":"Infectious disease threats in the twenty-first century: strengthening the global response.","volume":"10","author":"Bloom","year":"2019","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.micinf.2020.02.002","article-title":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future.","volume":"22","author":"Li","year":"2020","journal-title":"Microbes Infect."},{"key":"B4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.cll.2004.05.008","article-title":"Major factors affecting the emergence and re-emergence of infectious diseases.","volume":"24","author":"Church","year":"2004","journal-title":"Clin Lab Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tvjl.2017.12.021","article-title":"Climate change and multiple emerging infectious diseases.","volume":"234","author":"Heffernan","year":"2018","journal-title":"Vet J."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.onehlt.2018.100080","article-title":"Infectious disease and economics: the case for considering multi-sectoral impacts.","volume":"7","author":"Smith","year":"2019","journal-title":"One Health."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1073\/pnas.1701410114","article-title":"emerging infectious diseases: a proactive approach.","volume":"114","author":"Bloom","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome.","volume":"348","author":"Drosten","year":"2003","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000436","article-title":"Characterizing the epidemiology of the 2009 influenza A\/H1N1 pandemic in Mexico.","volume":"8","author":"Chowell","year":"2011","journal-title":"PLoS Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle east respiratory syndrome.","volume":"386","author":"Zumla","year":"2015","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/769121","article-title":"Ebola virus disease 2013-2014 outbreak in West Africa: an analysis of the epidemic spread and response.","volume":"2015","author":"Cenciarelli","year":"2015","journal-title":"Int J Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1590\/0074-02760150192","article-title":"First report of autochthonous transmission of Zika virus in Brazil.","volume":"110","author":"Zanluca","year":"2015","journal-title":"Mem Inst Oswaldo Cruz."},{"key":"B13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aau9343","article-title":"Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak.","volume":"363","author":"Kafetzopoulou","year":"2019","journal-title":"Science."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak \u2013 an update on the status.","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res."},{"key":"B15","year":"2020","journal-title":"R&D Blueprint."},{"key":"B16","year":"2020","journal-title":"NIAID Emerging Infectious Diseases\/Pathogens."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations.","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases.","volume":"451","author":"Jones","year":"2008","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau5294","article-title":"Urbanization affects peak timing, prevalence, and bimodality of influenza pandemics in Australia: results of a census-calibrated model.","volume":"4","author":"Zachreson","year":"2018","journal-title":"Sci Adv."},{"key":"B20","year":"2020","journal-title":"Principles of Epidemiology in Public Health Practice. An Introduction to Applied Epidemiology and Biostatistics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/153036604773083004","article-title":"The epidemic of West Nile virus in the United States, 2002.","volume":"4","author":"O\u2019Leary","year":"2004","journal-title":"Vector Borne Zoonotic Dis."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay096","article-title":"West Nile in Europe: an increasing public health problem.","volume":"25","author":"Barrett","year":"2018","journal-title":"J Travel Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijid.2016.05.014","article-title":"Zika virus, vectors, reservoirs, amplifying hosts, and their potential to spread worldwide: what we know and what we should investigate urgently.","volume":"48","author":"Vorou","year":"2016","journal-title":"Int J Infect Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/INF.0000000000001486","article-title":"Microcephaly case fatality rate associated with Zika Virus infection in Brazil: current estimates.","volume":"36","author":"Cunha","year":"2017","journal-title":"Pediatr Infect Dis J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cll.2010.01.001","article-title":"Yellow fever: a reemerging threat.","volume":"30","author":"Gardner","year":"2010","journal-title":"Clin Lab Med."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11280.2","article-title":"Yellow fever in the Americas: the growing concern about new epidemics.","volume":"6","author":"Ortiz-Mart\u00ednez","year":"2017","journal-title":"F1000Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.actatropica.2016.11.020","article-title":"The emergence of arthropod-borne viral diseases: a global prospective on dengue, chikungunya and zika fevers.","volume":"166","author":"Mayer","year":"2017","journal-title":"Acta Trop."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-018-2830-8","article-title":"History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review.","volume":"11","author":"Salles","year":"2018","journal-title":"Parasit Vectors."},{"key":"B29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1017\/S0950268808001167","article-title":"Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on R\u00e9union.","volume":"137","author":"Economopoulou","year":"2009","journal-title":"Epidemiol Infect."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.368.6492.695","article-title":"Growth of cities could boost mosquito-borne diseases.","volume":"368","author":"Pennisi","year":"2020","journal-title":"Science."},{"key":"B31","first-page":"1","article-title":"Lassa fever in West African sub-region: an overview.","volume":"44","author":"Ogbu","year":"2007","journal-title":"J Vector Borne Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3201\/eid2506.181035","article-title":"Epidemiologic and clinical features of lassa fever outbreak in Nigeria, January 1-May 6, 2018.","volume":"25","author":"Ilori","year":"2019","journal-title":"Emerg Infect Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.aogh.2015.02.005","article-title":"Transmission of ebola virus disease: an overview.","volume":"80","author":"Rewar","year":"2014","journal-title":"Ann Glob Health."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3390\/v4101878","article-title":"Forty-five years of Marburg virus research.","volume":"4","author":"Brauburger","year":"2012","journal-title":"Viruses."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0297","article-title":"The Ebola outbreak, 2013-2016: old lessons for new epidemics.","volume":"372","author":"Coltart","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2045-6","article-title":"How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence.","volume":"16","author":"Nyakarahuka","year":"2016","journal-title":"BMC Infect Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1126\/science.1176225","article-title":"Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.","volume":"325","author":"Garten","year":"2009","journal-title":"Science."},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3201\/eid1201.050979","article-title":"1918 Influenza: the mother of all pandemics.","volume":"12","author":"Taubenberger","year":"2006","journal-title":"Emerg Infect Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1473-3099(12)70121-4","article-title":"Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study.","volume":"12","author":"Dawood","year":"2012","journal-title":"Lancet Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-317","article-title":"Predictors of fatality in pandemic influenza A (H1N1) virus infection among adults.","volume":"14","author":"Erg\u00f6n\u00fcl","year":"2014","journal-title":"BMC Infect Dis."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000388","article-title":"Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study.","volume":"8","author":"Valenciano","year":"2011","journal-title":"PLoS Med."},{"key":"B42","year":"2020","journal-title":"2009 H1N1 Pandemic (H1N1pdm09 Virus)."},{"key":"B43","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses.","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat Rev Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1080\/22221751.2020.1736644","article-title":"A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses.","volume":"9","author":"Fung","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"B45","year":"2019","journal-title":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV)."},{"key":"B46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2.","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet."},{"key":"B48","year":"2020","journal-title":"Mortality Analyses."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1080\/21645515.2019.1661209","article-title":"Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases.","volume":"15","author":"Maslow","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination.","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/microbiolspec.PoH-0004-2014","article-title":"History of smallpox and its spread in human populations","volume":"4","author":"Th\u00e8ves","year":"2016","journal-title":"Paleomicrobiology of Humans."},{"key":"B52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/vaccines3020373","article-title":"Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines.","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines."},{"key":"B53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Rapid development of an inactivated vaccine candidate for SARS-CoV-2.","volume":"369","author":"Gao","year":"2020","journal-title":"Science."},{"key":"B54","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases.","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol Ther."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases.","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2013 a new era in vaccinology.","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection.","volume":"168","author":"Richner","year":"2017","journal-title":"Cell."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies.","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat Commun."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses.","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161193","article-title":"Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge.","volume":"11","author":"Magini","year":"2016","journal-title":"PLoS One."},{"key":"B61","doi-asserted-by":"publisher","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1016\/j.vaccine.2014.05.053","article-title":"A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model.","volume":"32","author":"Khalil","year":"2014","journal-title":"Vaccine."},{"key":"B63","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape.","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B64","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report.","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1679","article-title":"Covid-19: what do we know so far about a vaccine?","volume":"369","author":"Mahase","year":"2020","journal-title":"BMJ."},{"key":"B66","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity.","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev Vaccines."},{"key":"B67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.actbio.2018.08.033","article-title":"Engineering DNA vaccines against infectious diseases.","volume":"80","author":"Lee","year":"2018","journal-title":"Acta Biomater."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/mt.2013.61","article-title":"Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.","volume":"21","author":"Shedlock","year":"2013","journal-title":"Mol Ther."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci Transl Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J Infect Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.vaccine.2011.10.085","article-title":"Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.","volume":"30","author":"Porter","year":"2012","journal-title":"Vaccine."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000928","article-title":"A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.","volume":"5","author":"Mallilankaraman","year":"2011","journal-title":"PLoS Negl Trop Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques.","volume":"369","author":"Yu","year":"2020","journal-title":"Science."},{"key":"B74","year":"2020","journal-title":"Draft Landscape of COVID-19 Candidate Vaccines."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.","author":"Blanchard","year":"1998","journal-title":"J Gen Virol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer.","volume":"8","author":"Draper","year":"2010","journal-title":"Nat Rev Microbiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact.","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr Opin Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nm.1850","article-title":"Effective induction of high-titer antibodies by viral vector vaccines.","volume":"14","author":"Draper","year":"2008","journal-title":"Nat Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis.","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet."},{"key":"B80","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector ebola vaccine.","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N Engl J Med."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.","volume":"7","author":"Green","year":"2015","journal-title":"Sci Transl Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases.","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology."},{"key":"B83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijid.2017.10.010","article-title":"Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: a single-arm, single-center study.","volume":"66","author":"Vu","year":"2018","journal-title":"Int J Infect Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease.","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10295-013-1235-0","article-title":"Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells.","volume":"40","author":"Berlec","year":"2013","journal-title":"J Ind Microbiol Biotechnol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0264-410x(88)80022-7","article-title":"Application of recombinant DNA techniques in the development of viral vaccines.","volume":"6","author":"Murray","year":"1988","journal-title":"Vaccine."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1126\/science.8248784","article-title":"The influence of antigen organization on B cell responsiveness.","volume":"262","author":"Bachmann","year":"1993","journal-title":"Science."},{"key":"B88","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.virol.2010.08.026","article-title":"HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFN\u03b3 production by CD4+ T cells.","volume":"407","author":"Caivano","year":"2010","journal-title":"Virology."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047492","article-title":"Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses.","volume":"7","author":"Chua","year":"2012","journal-title":"PLoS One."},{"key":"B91","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/QAI.0b013e31820b844e","article-title":"CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells.","volume":"56","author":"Franco","year":"2011","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B92","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nbt0195-53","article-title":"Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus.","volume":"13","author":"Turpen","year":"1995","journal-title":"Biotechnology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1073\/pnas.94.11.5784","article-title":"Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1.","volume":"94","author":"Yusibov","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B94","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","article-title":"The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza.","volume":"8","author":"D\u2019Aoust","year":"2010","journal-title":"Plant Biotechnol J."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001556","article-title":"Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.","volume":"3","author":"Gregson","year":"2008","journal-title":"PLoS One."},{"key":"B96","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms.","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr Opin Virol."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development.","volume":"55","author":"Kim","year":"2020","journal-title":"EBioMedicine."},{"key":"B98","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.1016\/j.vaccine.2020.06.066","article-title":"Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.","volume":"38","author":"Ren","year":"2020","journal-title":"Vaccine."},{"key":"B99","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.vetmic.2013.03.005","article-title":"Explosive spread of a neuroinvasive lineage 2 West Nile virus in central Europe, 2008\/2009.","volume":"165","author":"Bakonyi","year":"2013","journal-title":"Vet Microbiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3201\/eid1402.070457","article-title":"Genetic determinants of virulence in pathogenic lineage 2 West Nile virus strains.","volume":"14","author":"Botha","year":"2008","journal-title":"Emerg Infect Dis."},{"key":"B101","first-page":"221","article-title":"Equine vaccine for West Nile virus.","volume":"114","author":"Ng","year":"2003","journal-title":"Dev Biol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.vetimm.2008.02.002","article-title":"A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.","volume":"123","author":"El Garch","year":"2008","journal-title":"Vet Immunol Immunopathol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1016\/j.vaccine.2018.12.026","article-title":"An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.","volume":"37","author":"Woods","year":"2019","journal-title":"Vaccine."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys.","volume":"16","author":"Lieberman","year":"2009","journal-title":"Clin Vaccine Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.3390\/v5123048","article-title":"Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.","volume":"5","author":"Dayan","year":"2013","journal-title":"Viruses."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.vaccine.2016.02.042","article-title":"Immunogenicity and protective efficacy of recombinant modified vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.","volume":"34","author":"Volz","year":"2016","journal-title":"Vaccine."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1086\/523650","article-title":"A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.","volume":"196","author":"Martin","year":"2007","journal-title":"J Infect Dis."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/v11090823","article-title":"Twenty years of progress toward west nile virus vaccine development.","volume":"11","author":"Kaiser","year":"2019","journal-title":"Viruses."},{"key":"B109","author":"Coller","year":"2012","journal-title":"A1: Recombinant Subunit West Nile Virus Vaccine for Protection of Human Subjects."},{"key":"B110","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1016\/j.vaccine.2018.12.020","article-title":"Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.","volume":"37","author":"Quintel","year":"2019","journal-title":"Vaccine."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00720-19","article-title":"Replication-defective West Nile virus with NS1 deletion as a new vaccine platform for flavivirus.","volume":"93","author":"Li","year":"2019","journal-title":"J Virol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1056\/NEJMoa1600651","article-title":"Zika virus associated with microcephaly.","volume":"374","author":"Mlakar","year":"2016","journal-title":"N Engl J Med."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00737-8","article-title":"A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage.","volume":"8","author":"Shan","year":"2017","journal-title":"Nat Commun."},{"key":"B114","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nm.4322","article-title":"A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models.","volume":"23","author":"Shan","year":"2017","journal-title":"Nat Med."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35724-6","article-title":"A vaccine based on a modified vaccinia virus Ankara vector expressing Zika virus structural proteins controls Zika virus replication in mice.","volume":"8","author":"P\u00e9rez","year":"2018","journal-title":"Sci Rep."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1128\/JVI.02950-14","article-title":"Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.","volume":"89","author":"Abbink","year":"2015","journal-title":"J Virol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.","volume":"353","author":"Abbink","year":"2016","journal-title":"Science."},{"key":"B118","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ebiom.2016.09.028","article-title":"Preventative vaccines for Zika virus outbreak: preliminary evaluation.","volume":"13","author":"Kim","year":"2016","journal-title":"EBioMedicine."},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/v10110631","article-title":"Recent advances in Zika virus vaccines.","volume":"10","author":"Garg","year":"2018","journal-title":"Viruses."},{"key":"B120","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1073\/pnas.84.7.2019","article-title":"Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it.","volume":"84","author":"Hahn","year":"1987","journal-title":"Proc Natl Acad Sci USA."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day.","volume":"19","author":"Collins","year":"2017","journal-title":"Curr Infect Dis Rep."},{"key":"B123","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4161\/hv.6.9.12739","article-title":"Development of Sanofi Pasteur tetravalent dengue vaccine.","volume":"6","author":"Guy","year":"2010","journal-title":"Hum Vaccin."},{"key":"B124","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine."},{"key":"B125","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.3277268","article-title":"Pathogenesis of dengue: challenges to molecular biology.","volume":"239","author":"Halstead","year":"1988","journal-title":"Science."},{"key":"B126","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans.","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2101","article-title":"Dengue: status of current and under-development vaccines.","volume":"30","author":"Redoni","year":"2020","journal-title":"Rev Med Virol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02881","article-title":"Recent progress in vaccine development against Chikungunya virus.","volume":"10","author":"Gao","year":"2019","journal-title":"Front Microbiol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1128\/jvi.74.15.6777-6783.2000","article-title":"Effective vaccine for lassa fever.","volume":"74","author":"Fisher-Hoch","year":"2000","journal-title":"J Virol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2019.03.008","article-title":"Vaccine platforms for the prevention of Lassa fever.","volume":"215","author":"Purushotham","year":"2019","journal-title":"Immunol Lett."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw3163","article-title":"Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.","volume":"11","author":"Mateo","year":"2019","journal-title":"Sci Transl Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0140-6736(77)92002-5","article-title":"Isolation of marburg-like virus from a case of haemorrhagic fever in Zaire.","volume":"1","author":"Pattyn","year":"1977","journal-title":"Lancet."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola.","volume":"382","author":"Feldmann","year":"2020","journal-title":"N Engl J Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1016\/j.vaccine.2017.07.054","article-title":"Vaccines against Ebola virus.","volume":"36","author":"Venkatraman","year":"2018","journal-title":"Vaccine."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0295","article-title":"A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?","volume":"372","author":"Lambe","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/v8040094","article-title":"Virus-like particle vaccination protects nonhuman primates from lethal aerosol exposure with marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).","volume":"8","author":"Dye","year":"2016","journal-title":"Viruses."},{"key":"B138","doi-asserted-by":"publisher","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.","volume":"84","author":"Geisbert","year":"2010","journal-title":"J Virol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection against marburg virus using a recombinant VSV-vaccine depends on T and B cell activation.","volume":"9","author":"Marzi","year":"2019","journal-title":"Front Immunol."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01190-17","article-title":"Single-dose trivalent vesiculovax vaccine protects macaques from lethal Ebolavirus and Marburgvirus challenge.","volume":"92","author":"Matassov","year":"2018","journal-title":"J Virol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1089\/vim.2014.0071","article-title":"Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.","volume":"28","author":"Martins","year":"2015","journal-title":"Viral Immunol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejpb.2018.06.001","article-title":"Stability and suitability for storage and distribution of Ad26.ZEBOV\/MVA-BN\u00ae-Filo heterologous prime-boost Ebola vaccine.","volume":"129","author":"Capelle","year":"2018","journal-title":"Eur J Pharm Biopharm."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1186\/s12900-015-0035-3","article-title":"Human Coronavirus OC43 3CL Protease and the potential of ML188 as a broad-spectrum lead compound: homology modelling and molecular dynamic studies.","volume":"15","author":"Berry","year":"2015","journal-title":"BMC Struct Biol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses.","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"B146","year":"2020","journal-title":"Disease Briefing: Coronaviruses."},{"key":"B147","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019.","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coviro.2014.01.010","article-title":"MERS: emergence of a novel human coronavirus.","volume":"5","author":"Raj","year":"2014","journal-title":"Curr Opin Virol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/path.4454","article-title":"Molecular pathology of emerging coronavirus infections.","volume":"235","author":"Gralinski","year":"2015","journal-title":"J Pathol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development.","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus.","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.","volume":"495","author":"Raj","year":"2013","journal-title":"Nature."},{"key":"B153","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus Infections and Immune Responses.","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges.","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"B155","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(20)30260-9","article-title":"Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.","volume":"395","author":"Wu","year":"2020","journal-title":"Lancet."},{"key":"B156","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0140-6736(20)30374-3","article-title":"WHO scientific and technical advisory group for infectious hazards. COVID-19: what is next for public health?","volume":"395","author":"Heymann","year":"2020","journal-title":"Lancet."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMc2004973","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.","volume":"382","author":"van Doremalen","year":"2020","journal-title":"N Engl J Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/s0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated sars pneumonia: a prospective study.","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00763-2020","article-title":"Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset.","author":"Lou","year":"2020","journal-title":"Eur Respir J."},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-018-0940-8","article-title":"Efficacy of genogroup 1 based porcine epidemic diarrhea live vaccine against genogroup 2 field strain in Japan.","volume":"15","author":"Sato","year":"2018","journal-title":"Virol J."},{"key":"B161","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19.","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med."},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100040","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients.","volume":"1","author":"Suthar","year":"2020","journal-title":"Cell Rep Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: where are we?","volume":"8","author":"Roper","year":"2009","journal-title":"Expert Rev Vaccines."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/v11010059","article-title":"From SARS to MERS, thrusting coronaviruses into the spotlight.","volume":"11","author":"Song","year":"2019","journal-title":"Viruses."},{"key":"B165","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","article-title":"Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments\u2013the importance of immunofocusing in subunit vaccine design.","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine."},{"key":"B166","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.virusres.2014.11.013","article-title":"Receptor-binding domain-based subunit vaccines against MERS-CoV.","volume":"202","author":"Zhang","year":"2015","journal-title":"Virus Res."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.vaccine.2014.02.004","article-title":"Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines.","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine."},{"key":"B168","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"B169","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/21645515.2017.1389362","article-title":"Development of Middle East respiratory syndrome coronavirus vaccines - advances and challenges.","volume":"14","author":"Cho","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3390\/v11010074","article-title":"Middle East respiratory syndrome vaccine candidates: cautious optimism.","volume":"11","author":"Schindewolf","year":"2019","journal-title":"Viruses."},{"key":"B171","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1126\/science.abc4776","article-title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques.","volume":"369","author":"Chandrashekar","year":"2020","journal-title":"Science."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19.","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1073\/pnas.0307140101","article-title":"Potent neutralization of severe acute respiratory syndrome (SARS) Coronavirus by a human mAb to S1 protein that blocks receptor association.","volume":"101","author":"Sui","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"B174","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.1128\/JVI.00912-14","article-title":"Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.","volume":"88","author":"Ying","year":"2014","journal-title":"J Virol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"13892","DOI":"10.1128\/JVI.02448-13","article-title":"Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.","volume":"87","author":"Ohnuma","year":"2013","journal-title":"J Virol."},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection.","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun."},{"key":"B177","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature."},{"key":"B178","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike.","volume":"584","author":"Liu","year":"2020","journal-title":"Nature."},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.","author":"Lv","year":"2020","journal-title":"Science."},{"key":"B180","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","article-title":"Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients.","volume":"182","author":"Kreer","year":"2020","journal-title":"Cell."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01531","article-title":"Nanobodies: prospects of expanding the gamut of neutralizing antibodies against the novel coronavirus, SARS-CoV-2.","volume":"11","author":"Konwarh","year":"2020","journal-title":"Front Immunol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies.","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell."},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00089-20","article-title":"T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species.","volume":"94","author":"Grifoni","year":"2020","journal-title":"J Virol."},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00517","article-title":"Two is better than one: evidence for T-cell cross-protection between dengue and zika and implications on vaccine design.","volume":"11","author":"Subramaniam","year":"2020","journal-title":"Front Immunol."},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00185","article-title":"Strong CD4 T cell responses to Zika virus antigens in a cohort of dengue virus immune mothers of congenital zika virus syndrome infants.","volume":"11","author":"Reynolds","year":"2020","journal-title":"Front Immunol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika-dengue virus antibody cross-neutralization.","volume":"536","author":"Barba-Spaeth","year":"2016","journal-title":"Nature."},{"key":"B187","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.aaf8505","article-title":"Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.","volume":"353","author":"Stettler","year":"2016","journal-title":"Science."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00334","article-title":"Cross-reactive immunity among flaviviruses.","volume":"11","author":"Rathore","year":"2020","journal-title":"Front Immunol."},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aan6809","article-title":"Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors.","volume":"2","author":"Rogers","year":"2017","journal-title":"Sci Immunol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat Immunol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.","volume":"356","author":"Bardina","year":"2017","journal-title":"Science."},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2017.68","article-title":"Zika virus infection confers protection against West Nile virus challenge in mice.","volume":"6","author":"V\u00e1zquez-Calvo","year":"2017","journal-title":"Emerg Microbes Infect."},{"key":"B193","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1080\/21645515.2019.1621149","article-title":"West Nile virus vaccines \u2013 current situation and future directions.","volume":"15","author":"Ulbert","year":"2019","journal-title":"Hum Vaccin Immunother."},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02991","article-title":"Viral-induced enhanced disease illness.","volume":"9","author":"Smatti","year":"2018","journal-title":"Front Microbiol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/icb.1964.44","article-title":"Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls.","volume":"42","author":"Hawkes","year":"1964","journal-title":"Aust J Exp Biol Med Sci."},{"key":"B196","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/0042-6822(67)90144-4","article-title":"The enhancement of virus infectivity by antibody.","volume":"33","author":"Hawkes","year":"1967","journal-title":"Virology."},{"key":"B197","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1084\/jem.158.1.258","article-title":"Complement receptor mediates enhanced flavivirus replication in macrophages.","volume":"158","author":"Cardosa","year":"1983","journal-title":"J Exp Med."},{"key":"B198","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/rmv.405","article-title":"Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications.","volume":"13","author":"Takada","year":"2003","journal-title":"Rev Med Virol."},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006565","article-title":"Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody.","volume":"13","author":"Houser","year":"2017","journal-title":"PLoS Pathog."},{"key":"B200","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment.","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science."},{"key":"B201","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol."},{"key":"B202","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.4049\/jimmunol.151.4.2032","article-title":"Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.","volume":"151","author":"Graham","year":"1993","journal-title":"J Immunol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1086\/374604","article-title":"Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model.","volume":"187","author":"Ponnuraj","year":"2003","journal-title":"J Infect Dis."},{"key":"B204","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nm1456","article-title":"A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines.","volume":"12","author":"Moghaddam","year":"2006","journal-title":"Nat Med."},{"key":"B205","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm918","article-title":"A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.","volume":"9","author":"Polack","year":"2003","journal-title":"Nat Med."},{"key":"B206","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med."},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119509","article-title":"A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.","volume":"10","author":"Lambert","year":"2015","journal-title":"PLoS One."},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-82","article-title":"Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus.","volume":"11","author":"Yip","year":"2014","journal-title":"Virol J."},{"key":"B209","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.","volume":"451","author":"Wang","year":"2014","journal-title":"Biochem Biophys Res Commun."},{"key":"B210","doi-asserted-by":"publisher","first-page":"e2015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry.","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion.","volume":"176","author":"Walls","year":"2019","journal-title":"Cell."},{"key":"B212","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS Coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates.","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect Dis."},{"key":"B213","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/cei.13295","article-title":"Emerging viruses and current strategies for vaccine intervention.","volume":"196","author":"Afrough","year":"2019","journal-title":"Clin Exp Immunol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1586\/14760584.2016.1106942","article-title":"Self-disseminating vaccines for emerging infectious diseases.","volume":"15","author":"Murphy","year":"2016","journal-title":"Expert Rev Vaccines."},{"key":"B215","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.vaccine.2015.03.029","article-title":"A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.","volume":"33","author":"Tsuda","year":"2015","journal-title":"Vaccine."},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02936","article-title":"Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations.","volume":"9","author":"S\u00e1nchez-Ram\u00f3n","year":"2018","journal-title":"Front Immunol."},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease.","volume":"352","author":"Netea","year":"2016","journal-title":"Science."},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020456","article-title":"Infectious agents as stimuli of trained innate immunity.","volume":"19","author":"Rusek","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1086\/657144","article-title":"Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic.","volume":"202","author":"Chien","year":"2010","journal-title":"J Infect Dis."},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.05.20054163","article-title":"Mandated bacillus calmette-gu\u00e9rin (BCG) vaccination predicts flattened curves for the spread of COVID-19.","author":"Berg","year":"2020","journal-title":"MedRxiv"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102565","article-title":"Trained innate immunity not always amicable.","volume":"20","author":"W\u0142odarczyk","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-01247-2","article-title":"Scores of coronavirus vaccines are in competition \u2013 how will scientists choose the best?","author":"Callaway","year":"2020","journal-title":"Nature."},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00107","article-title":"The future of flu: a review of the human challenge model and systems biology for advancement of influenza vaccinology.","volume":"9","author":"Sherman","year":"2019","journal-title":"Front Cell Infect Microbiol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm0815-828","article-title":"Challenge accepted: human challenge trials for dengue.","volume":"21","author":"Yan","year":"2015","journal-title":"Nat Med."},{"key":"B225","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1016\/j.vaccine.2020.04.073","article-title":"Tortoises, hares, and vaccines: a cautionary note for SARS-CoV-2 vaccine development.","volume":"38","author":"Poland","year":"2020","journal-title":"Vaccine."},{"key":"B226","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.chom.2020.04.022","article-title":"Rational vaccine design in the time of COVID-19.","volume":"27","author":"Burton","year":"2020","journal-title":"Cell Host Microbe."},{"key":"B227","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1126\/science.abc5312","article-title":"A strategic approach to COVID-19 vaccine R&D.","volume":"368","author":"Corey","year":"2020","journal-title":"Science."},{"key":"B228","author":"Porta","year":"2008","journal-title":"A Dictionary of Epidemiology."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02130\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T16:06:51Z","timestamp":1696608411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02130\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":228,"alternative-id":["10.3389\/fimmu.2020.02130"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.02130","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"article-number":"2130"}}